Prostate and other male cancers:
Indications for Leuprolide acetate:
Palliative treatment of advanced prostatic carcinoma.
1mg SC daily. Rotate inj site.
Women. Pregnancy (Cat.X).
Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Risk of QT prolongation: long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities, or CHF, and concomitant Class IA or III antiarrhythmics. Instruct patient on correct self administration.
Concomitant Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics may prolong the QT interval.
Hot flashes/sweats, inj site reaction, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI upset, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, spinal cord compression; hyperglycemia, anaphylactoid, photosensitivity.